Shang­hai's Ab­bisko out-li­cens­es EGFR can­di­date in po­ten­tial­ly nine-fig­ure deal

A Shang­hai-based biotech is hand­ing off rights to one of its can­di­dates to an­oth­er Shang­hai com­pa­ny.

Qim­ing-backed Ab­bisko — head­ed by Eli Lil­ly and No­var­tis vet­er­an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER